ClinicalTrials.gg
RecruitingNCT06536868Updated Apr 24, 2026

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

A Phase 2 interventional study of Tislelizumab and Etoposide in Extensive-stage Small-cell Lung Cancer, sponsored by Second Hospital of Shanxi Medical University. Recruiting at 6 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Second Hospital of Shanxi Medical University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing tislelizumab in Small Cell Lung Carcinoma — 9 open to participants now, 11 under way, none of them phase 3. tislelizumab · Small Cell Lung Carcinoma.

Planned enrollment
5th of 14
40 · median 34
Started
2024
with 1 other
Phase 2
11 of 14
7 open now
Primary completion
2026-12
later than 5 of 10 live
Registered
9th of 14
by date
Lead sponsor
1 of 14
Second Hospital of Shanxi Medical University

Among the 14 studies testing tislelizumab in Small Cell Lung Carcinoma, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 11 in phase 2, reaches primary completion later than 5 of the 10 other live ones, and was the 9th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

9 of the 14 studies testing tislelizumab in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing tislelizumab in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.

03

Conditions studied

  • Extensive-stage Small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 to 80 years old (inclusive of 18th and 80th birthdays), male or female, at the time of signing the form;
  • Confirmed small cell lung cancer of extensive stage by histology or cytology;
  • At least one by imaging studies (according to 1.1) with a long diameter of ≥10 mm as examined by spiral CT or MRI;
  • Within 3 days prior to treatment, an score of 0 to 1;
  • No prior antitumor treatment for extensive stage disease (if the patient has previously received chemotherapy and/or radiotherapy in the limited stage of SCLC, the treatment intent must have been curative, and there must be at least a 6-month treatment-free interval between the end of chemotherapy, radiotherapy, or chemoradiotherapy and the diagnosis of extensive stage SCLC);
  • Expected life span of ≥3 months;
  • Good function of vital organs;
  • The subject voluntarily joins this study, signs the informed consent form, has good compliance, and cooperates with follow-up.

Exclusion criteria

Exclusion Criteria:

  • Concurrent severe respiratory diseases: such as pulmonary fibrosis;
  • Presence of psychiatric disorders, hematologic diseases, diseases, and severe primary diseases of the heart, brain, liver, or kidneys;
  • Uncontrolled active infections;
  • Known or suspected allergies to the study medication and its ;
  • Female patients who are pregnant or breastfeeding, or women of with a positive baseline pregnancy test;
  • Prior use of antitumor treatment targeting the PD-(L)1 pathway.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    ICI+EC/EP+TRT

    Drug: Tislelizumab Drug: Carboplatin Drug: Etoposide Radiation: Radiation therapy Drug: Cisplatin

    Drug: Tislelizumab · Drug: Etoposide · Drug: Carboplatin or Cisplatin · Radiation: Thoracic radiotherapy

Interventions

  • Tislelizumab infusion will be administered for 2 years (200mg, day1, Q3W).

  • Etoposide intravenous infusion will be administered during the induction phase (100mg/㎡, day1-3 Q3W for 4 cycles).

  • DrugCarboplatin or Cisplatin

    Drug pages: CarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Carboplatin or Cisplatin intravenous infusion will be administered during the induction phase (Carboplatin AUC5, Q3W for 4 cycles; Cisplatin 75mg/㎡, Q3W for 4 cycles).

  • RadiationThoracic radiotherapy

    IMRT 30-45Gy/10-15f

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    From the date of enrollment to the date of disease progression

    Time frame: Up to 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR as assessed by the Investigator according to RECIST v1.1

    Time frame: Up to 2 years

  2. Disease Control Rate (DCR)

    DCR as assessed by the Investigator according to RECIST v1.1

    Time frame: Up to 2 years

  3. Overall Survival (OS)

    From the date of enrollment until death by any cause or last follow-up

    Time frame: Up to 2 years

  4. Adverse events

    Treatment-related adverse events according to CTCAE 5.0.

    Time frame: Up to 2 years

07

Study locations

6 of 6 sites recruiting
  • Jincheng General Hospital
    Jincheng, Shanxi 048000, China
    Recruiting
    • Xueqin Li, Dr. · Contact+86 356 3661360
  • Jinzhong third people's hospital
    Jinzhong, Shanxi 032000, China
    Recruiting
    • Qian Wu, Dr. · Contact+86 354 3532157
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030000, China
    Recruiting
    • Gang Jin, Dr. · Contact+86 351 3365422
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030000, China
    Recruiting
    • Huijing Feng, Dr. · Contact+86 351 8368114
  • Shanxi Hospital of Traditional Chinese Medicine
    Taiyuan, Shanxi 030000, China
    Recruiting
    • Jinyang Bai, Dr. · Contact+86 351 303009
  • TISCO General Hospital
    Taiyuan, Shanxi 030000, China
    Recruiting
    • Weihua Jia, Dr. · Contact+86 351 3012448
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 150 non-industry phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 28 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2024
First posted
Aug 5, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06536868
Lead sponsor
Second Hospital of Shanxi Medical University
Responsible party
Gang Jin (Dr., Second Hospital of Shanxi Medical University) — Principal investigator
First posted
Aug 5, 2024
Start date
Aug 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 24, 2026

Study contacts

Gang Jin, Dr.
Contact
jingang2018@sina.com
+86 351 3365422
Chen Zhang
Contact
jingang2018@sina.com
+86 351 3365422
Gang Jin, Dr.
principal investigator · Second Hospital of Shanxi Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion